+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.

      Current Opinion in Rheumatology

      Antirheumatic Agents, administration & dosage, pharmacokinetics, therapeutic use, Arthritis, Rheumatoid, drug therapy, immunology, metabolism, Calcineurin Inhibitors, Cyclosporine, Drug Therapy, Combination, Glucocorticoids, Humans, Immunosuppressive Agents, Methotrexate, Safety, T-Lymphocytes, drug effects, Tacrolimus, Tacrolimus Binding Proteins

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The calcineurin inhibitors cyclosporine and tacrolimus are important treatments for patients with active rheumatoid arthritis, especially in cases of resistance or intolerance to methotrexate or other disease-modifying antirheumatic drugs. Here, we discuss the mechanism, efficacy and safety of cyclosporine and tacrolimus in the treatment of rheumatoid arthritis. Recent clinical trials of cyclosporine have shown the advantages of its combination with methotrexate, glucocorticoids and leflunomide in the treatment of active rheumatoid arthritis. In Japan, tacrolimus monotherapy was found to be quite effective and combination therapy with methotrexate had positive results in an American study. The inhibitory effects of both drugs not only on T lymphocytes, but also on human osteoclast formation, have been demonstrated in basic studies. Cyclosporine and tacrolimus are clinically available disease-modifying antirheumatic drugs. Numerous clinical studies have shown the usefulness of these calcineurin inhibitors in monotherapy and also when combined with methotrexate. Although these drugs have similar effects, there are some differences in adverse reactions.

          Related collections

          Author and article information



          Comment on this article